Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/125358
Title: | The 5% Lidocaine-medicated Plaster: Its Inclusion In International Treatment Guidelines For Treating Localized Neuropathic Pain, and Clinical Evidence Supporting Its Use |
Author: | Baron, Ralf Allegri, Massimo Correa Illanes, Gerardo Hans, Guy Serpell, Michael Mick, Gerard Mayoral Rojals, Victor |
Keywords: | Dolor Malalties del sistema nerviós Pain Nervous system Diseases |
Issue Date: | 1-Dec-2016 |
Publisher: | Springer |
Abstract: | When peripheral neuropathic pain affects a specific, clearly demarcated area of the body, it may be described as localized neuropathic pain (LNP). Examples include postherpetic neuralgia and painful diabetic neuropathy, as well as post-surgical and post-traumatic pain. These conditions may respond to topical treatment, i.e., pharmaceutical agents acting locally on the peripheral nervous system, and the topical route offers advantages over systemic administration. Notably, only a small fraction of the dose reaches the systemic circulation, thereby reducing the risk of systemic adverse effects, drug-drug interactions and overdose. From the patient's perspective, the analgesic agent is easily applied to the most painful area(s). The 5% lidocaine-medicated plaster has been used for several years to treat LNP and is registered in approximately 50 countries. Many clinical guidelines recommend this treatment modality as a first-line option for treating LNP, particularly in frail and/or elderly patients and those receiving multiple medications, because the benefit-to-risk ratios are far better than those of systemic analgesics. However, some guidelines make only a weak recommendation for its use. This paper considers the positioning of the 5% lidocaine-medicated plaster in international treatment guidelines and how they may be influenced by the specific criteria used in developing them, such as the methodology employed by randomized, placebo-controlled trials. It then examines the body of evidence supporting use of the plaster in some prevalent LNP conditions. Common themes that emerge from clinical studies are: (1) the excellent tolerability and safety of the plaster, which can increase patients' adherence to treatment, (2) continued efficacy over long-term treatment, and (3) significant reduction in the size of the painful area. On this basis, it is felt that the 5% lidocaine-medicated plaster should be more strongly recommended for treating LNP, either as one component of a multimodal approach or as monotherapy. |
Note: | Reproducció del document publicat a: https://doi.org/10.1007/s40122-016-0060-3 |
It is part of: | Pain and Therapy, 2016, vol. 5, num. 2, p. 149-169 |
URI: | http://hdl.handle.net/2445/125358 |
Related resource: | https://doi.org/10.1007/s40122-016-0060-3 |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) Publicacions de projectes de recerca finançats per la UE |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
BaronR.pdf | 601.81 kB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License